162 related articles for article (PubMed ID: 31198475)
1. DNA Methylation Profiles and Their Diagnostic Utility in BC.
Shan M; Zhang L; Liu Y; Gao C; Kang W; Yang W; He Y; Zhang G
Dis Markers; 2019; 2019():6328503. PubMed ID: 31198475
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation patterns of RAR-β2 and RASSF1A gene promoters in FNAB samples from Greek population with benign or malignant breast lesions.
Kougioumtsidou N; Vavoulidis E; Nasioutziki M; Symeonidou M; Pratilas GC; Mareti E; Petousis S; Chatzikyriakidou A; Grimbizis G; Theodoridis T; Miliaras D; Dinas K; Zepiridis L
Diagn Cytopathol; 2021 Jan; 49(1):153-164. PubMed ID: 32530576
[TBL] [Abstract][Full Text] [Related]
3. Methylcap-seq reveals novel DNA methylation markers for the diagnosis and recurrence prediction of bladder cancer in a Chinese population.
Zhao Y; Guo S; Sun J; Huang Z; Zhu T; Zhang H; Gu J; He Y; Wang W; Ma K; Wang J; Yu J
PLoS One; 2012; 7(4):e35175. PubMed ID: 22529986
[TBL] [Abstract][Full Text] [Related]
4. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel.
Dulaimi E; Uzzo RG; Greenberg RE; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Mar; 10(6):1887-93. PubMed ID: 15041703
[TBL] [Abstract][Full Text] [Related]
5. Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer.
Shan M; Yin H; Li J; Li X; Wang D; Su Y; Niu M; Zhong Z; Wang J; Zhang X; Kang W; Pang D
Oncotarget; 2016 Apr; 7(14):18485-94. PubMed ID: 26918343
[TBL] [Abstract][Full Text] [Related]
6. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
7. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas.
Furlan D; Carnevali I; Marcomini B; Cerutti R; Dainese E; Capella C; Riva C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3329-36. PubMed ID: 16740754
[TBL] [Abstract][Full Text] [Related]
8. Microarray-based analysis of whole-genome DNA methylation profiling in early detection of breast cancer.
Li SY; Wu HC; Mai HF; Zhen JX; Li GS; Chen SJ
J Cell Biochem; 2019 Jan; 120(1):658-670. PubMed ID: 30203578
[TBL] [Abstract][Full Text] [Related]
9. Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients.
Böck J; Appenzeller S; Haertle L; Schneider T; Gehrig A; Schröder J; Rost S; Wolf B; Bartram CR; Sutter C; Haaf T
Int J Cancer; 2018 Sep; 143(6):1416-1425. PubMed ID: 29659014
[TBL] [Abstract][Full Text] [Related]
10. Gene methylation in breast ductal fluid from BRCA1 and BRCA2 mutation carriers.
Antill YC; Mitchell G; Johnson SA; Devereux L; Milner A; Di Iulio J; Lindeman GJ; Kirk J; Phillips KA; Campbell IG
Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):265-74. PubMed ID: 20056647
[TBL] [Abstract][Full Text] [Related]
11. A DNA hypermethylation profile reveals new potential biomarkers for the evaluation of prognosis in urothelial bladder cancer.
López JI; Angulo JC; Martín A; Sánchez-Chapado M; González-Corpas A; Colás B; Ropero S
APMIS; 2017 Sep; 125(9):787-796. PubMed ID: 28586118
[TBL] [Abstract][Full Text] [Related]
12. HOXD13 methylation status is a prognostic indicator in breast cancer.
Zhong Z; Shan M; Wang J; Liu T; Xia B; Niu M; Ren Y; Pang D
Int J Clin Exp Pathol; 2015; 8(9):10716-24. PubMed ID: 26617782
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation patterns in bladder cancer and washing cell sediments: a perspective for tumor recurrence detection.
Negraes PD; Favaro FP; Camargo JL; Oliveira ML; Goldberg J; Rainho CA; Salvadori DM
BMC Cancer; 2008 Aug; 8():238. PubMed ID: 18702824
[TBL] [Abstract][Full Text] [Related]
14. Aberrant gene methylation in the lymph nodes provides a possible marker for diagnosing micrometastasis in gastric cancer.
Hiraki M; Kitajima Y; Sato S; Mitsuno M; Koga Y; Nakamura J; Hashiguchi K; Noshiro H; Miyazaki K
Ann Surg Oncol; 2010 Apr; 17(4):1177-86. PubMed ID: 19957042
[TBL] [Abstract][Full Text] [Related]
15. Detection of RASSF1A and RARbeta hypermethylation in serum DNA from breast cancer patients.
Shukla S; Mirza S; Sharma G; Parshad R; Gupta SD; Ralhan R
Epigenetics; 2006; 1(2):88-93. PubMed ID: 17998817
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
[TBL] [Abstract][Full Text] [Related]
17. Urine cell-based DNA methylation classifier for monitoring bladder cancer.
van der Heijden AG; Mengual L; Ingelmo-Torres M; Lozano JJ; van Rijt-van de Westerlo CCM; Baixauli M; Geavlete B; Moldoveanud C; Ene C; Dinney CP; Czerniak B; Schalken JA; Kiemeney LALM; Ribal MJ; Witjes JA; Alcaraz A
Clin Epigenetics; 2018; 10():71. PubMed ID: 29854012
[TBL] [Abstract][Full Text] [Related]
18. Pyrosequencing assays to study promoter CpG site methylation of the O6-MGMT, hMLH1, p14ARF, p16INK4a, RASSF1A, and APC1A genes.
Löf-Ohlin ZM; Nilsson TK
Oncol Rep; 2009 Mar; 21(3):721-9. PubMed ID: 19212632
[TBL] [Abstract][Full Text] [Related]
19. Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer.
Spitzwieser M; Holzweber E; Pfeiler G; Hacker S; Cichna-Markl M
Breast Cancer Res; 2015 Sep; 17(1):125. PubMed ID: 26370119
[TBL] [Abstract][Full Text] [Related]
20. Association between HIC1 and RASSF1A promoter hypermethylation with MTHFD1 G1958A polymorphism and clinicopathological features of breast cancer in Iranian patients.
Rasti M; Tavasoli P; Monabati A; Entezam M
Iran Biomed J; 2009 Oct; 13(4):199-206. PubMed ID: 19946345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
